DelfaGLP-1 Atlas

Lead sponsor

Janssen Research & Development, LLC

9 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

9

Trials led

0

Active

740,953

Total enrollment

82

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
5
Phase 2
2
Not applicable
2

Trials by status

Completed
8
Terminated
1

Trials led

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseEstablished CVDnot applicableCompleted714,582
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)Established CVDnot applicableCompleted25,358
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants—Ph 2Completed474
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes MellitusHbA1c 6.5-9.5%Ph 2Completed196
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)BMI 25-40Ph 1Completed188
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple DoseBMI 25-40Ph 1Completed52
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal FunctionBMI 18-40Ph 1Completed40
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes MellitusBMI 25-40Ph 1Completed39
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)HbA1c ≥6.5%Ph 1Terminated24